Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:10 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2545–2568 of 10,535 matching trials from the live ClinicalTrials.gov search.

Filters: Active, not recruiting Clear all

Conditions: Recurrent High-grade Glioma, Grade III Astrocytoma, Oligodendroglioma, Oligoastrocytoma, Ependymoma, Grade IV Astrocytoma
Interventions: exHSC, Nivolumab, Resection or biopsy; Biological · Drug · Procedure
Lead sponsor: University of Florida; Other
Eligibility: 4 Years to 26 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Pancreatic Cancer
Interventions: Stereotactic MRI-guided On-table Adaptive Radiation Therapy; Radiation
Lead sponsor: Viewray Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 12
States / cities: Los Angeles, California • Miami, Florida • Orlando, Florida + 8 more

Conditions: Autism Spectrum Disorder, Insomnia Chronic, Caregiver Burden
Interventions: Cognitive behavioral therapy for Insomnia; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 3 Years to 100 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex
Interventions: Cannabidiol; Drug
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: 1 Year and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 26
States / cities: Little Rock, Arkansas • Downey, California • Long Beach, California + 22 more

Conditions: Other Specified Injury of Thoracic Aorta
Interventions: Relay Pro Thoracic Stent-Graft System; Device
Lead sponsor: Bolton Medical; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 16
States / cities: Irvine, California • Stanford, California • New Haven, Connecticut + 13 more

Conditions: Thoracic Diseases, Aortic Aneurysm, Aortic Dissection, Thoracic Aortic Aneurysm, Thoracic Aortic Dissection
Interventions: Thoraflex Hybrid, RelayPro NBS; Device
Lead sponsor: Vascutek Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 352 participants
Timeline: 2023 – 2036
U.S. locations: 18
States / cities: Birmingham, Alabama • Los Angeles, California • Aurora, Colorado + 14 more

Conditions: Dementia, Decision Aids
Interventions: Decision aid; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Solid Tumor, Non Small Cell Lung Cancer, Neuroendocrine Carcinoma, Renal Cell Carcinoma (RCC)
Interventions: VSV-IFNβ-NIS, Pembrolizumab, ipilimumab + nivolumab; Biological
Lead sponsor: Vyriad, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Rochester, Minnesota • Cleveland, Ohio

Conditions: Advanced Malignant Solid Neoplasm, C-Reactive Protein Measurement, Cancer Fatigue, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Weight Loss
Interventions: Anamorelin Hydrochloride, Exercise Intervention, Laboratory Biomarker Analysis, Nutritional Assessment, Quality-of-Life Assessment, Questionnaire Administration; Drug · Behavioral · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Stroke, Acute
Interventions: Abduction Loading, Supported Reaching; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 3
States / cities: Chicago, Illinois • Wheaton, Illinois

Conditions: Multiple Sclerosis, Relapsing-Remitting
Interventions: Early Highly Effective Therapies Group, Escalation Therapies Group; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 60 Years
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Aurora, Colorado • Minneapolis, Minnesota • Rochester, Minnesota + 11 more

Conditions: Pancreatic Ductal Adenocarcinoma, Non-Small Cell Lung Cancer, Colorectal Cancer, Solid Tumor, KRAS G12V
Interventions: AFNT-211; Drug
Lead sponsor: Affini-T Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 10
States / cities: Los Angeles, California • New Haven, Connecticut • New York, New York + 5 more

Conditions: Locally Advanced Solid Tumor, Metastatic Tumor, Colorectal Adenocarcinoma
Interventions: TST003; Drug
Lead sponsor: Transcenta Therapeutics (Hangzhou) Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Portland, Oregon • Dallas, Texas • San Antonio, Texas

Conditions: Non-Small Cell Lung Cancer
Interventions: Osimertinib + Savolitinib, Savolitinib + Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 2
States / cities: Duarte, California • Sacramento, California

Conditions: Colorectal Cancer, Metastatic Cancer
Interventions: dexamethasone, floxuridine, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Spinocerebellar Ataxia
Interventions: Not listed
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 75 Years
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypereosinophilic Syndrome
Interventions: Benralizumab, Placebo; Biological
Lead sponsor: AstraZeneca; Industry
Eligibility: 12 Years to 130 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 8
States / cities: La Jolla, California • Atlanta, Georgia • Bethesda, Maryland + 5 more

Conditions: OTC Deficiency
Interventions: DTX301, Placebo, Oral Corticosteroids, Placebo for oral corticosteroids, Sodium Acetate; Genetic · Other · Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 12 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2031
U.S. locations: 4
States / cities: Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more

Conditions: Myeloma, Multiple
Interventions: Lenalidomide, Ixazomib, Daratumumab Injection, Dexamethasone; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years to 75 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: Bangor, Maine • Boston, Massachusetts • Omaha, Nebraska + 3 more

Conditions: Advanced Cancer
Interventions: Temsirolimus, Bevacizumab, Paclitaxel, Sorafenib, Carboplatin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Not listed
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: B-Cell Lymphoma, Large B-cell Lymphoma, DLBCL, Nos Genetic Subtypes, High-grade B Cell Lymphoma, Mediastinal Large B-cell Lymphoma
Interventions: 19(T2)28z1xx TRAC T cell; Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Stage 0
Interventions: Breast MRI, Laboratory Biomarker Analysis; Diagnostic Test · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 122 participants
Timeline: 2018 – 2032
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer
Interventions: PVX-410, Durvalumab, Hiltonol; Biological · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 5
States / cities: Tampa, Florida • Boston, Massachusetts • New York, New York

Conditions: AI-assisted Colonoscopy
Interventions: AI assisted colonoscopy, Conventional Colonoscopy; Device · Other
Lead sponsor: University of Oklahoma; Other
Eligibility: Not listed
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Search by objective public record fields.

Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma

Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer

Treatment to Improve Sleep in Caregivers With Insomnia and a Child With Autism

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Study of the Relay Pro® Thoracic Stent-Graft in Subjects With Traumatic Injury of the Descending Thoracic Aorta

Thoraflex Hybrid and Relay Extension Post-Approval Study

Decision Aid for Anti-Amyloid Therapy

Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors

Anamorelin Hydrochloride, Physical Activity, and Nutritional Counseling in Decreasing Cancer-Related Fatigue in Patients With Incurable Metastatic or Recurrent Solid Tumors

Progressive Abduction Loading Therapy

Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors

A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Wearable Gait Sensors

A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)

Clinical Study of DTX301 AAV-Mediated Gene Transfer for Ornithine Transcarbamylase (OTC) Deficiency

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer

Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma

MRI Characterization of Mammographically Detected DCIS

Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer

AI_Colonoscopy_for_Fellows